BIOPSY NEEDLE FOR TUMOR BLOOD FLOW QUANTIFICATION

该项目寻求将血流(灌流)传感器与 芯针和抽吸活检针。该设备(针、传感器、 仪器和软件)将作为调查的研究工具 肿瘤血流/氧合与抗肿瘤的关系 治疗结果。因为灌流是组织的主要介质 氧合作用，因为氧作为有效性的修饰物 在放射治疗和化疗药物中，灌流起着重要作用 这些疗法的结果。体温过高时，较高 治疗温度是在肿瘤血流低的时候实现的。 目前，还没有一种工具可以方便和常规地 结合抗癌治疗评估肿瘤血流灌注。在一个 研究环境，建议的设备将有助于确定这样的 存在灌流/治疗结果关系。在临床肿瘤学方面， 该设备将提供评估肿瘤成功与否的信息 血流调节剂，帮助计划抗肿瘤治疗 哺乳动物的有效性，并明确确保活组织检查是 取自活的、非坏死性组织。这款低成本的设备还将 允许在不增加患者的情况下收集灌注数据 种植正常周围组织的发病率或增加风险 肿瘤细胞的数量超过了标准的活组织检查程序。一种能力 在1-2 mm内检测较大尺寸的血管的传感器也可以 帮助引导活检针穿过组织以避开这些血管 在活组织检查路径中。此设备的未来版本可能包含 其他与临床相关的生理传感器。 建议的商业应用： 用于肿瘤测量的仪器式活检针 血流有可能预测非手术治疗的疗效 为美国数十万患者每人提供抗肿瘤治疗 年。这种装置应该会在许多研究中心得到广泛应用 研究动物模型和人类中的肿瘤血流。低成本的 活检针附件，用于量化组织活力和组织 缺血，并允许感测到靠近血管的血管 针尖助航，有望有很大的商业价值 潜力。

This project seeks to incorporate blood flow (perfusion) sensors with core and aspiration biopsy needles. This device (needle, sensor, instrument and software) will serve as a research tool to investigate the relationship between tumor blood flow/oxygenation and anti-tumor therapy outcome. Since perfusion is a primary mediator of tissue oxygenation, and since oxygen acts as a modifier of the effectiveness of radiation therapy and chemotherapeutic agents, perfusion plays a role in the outcome of these therapies. During hyperthermia, higher therapeutic temperatures are achieved when tumor flow is low. Currently, there does not exist a tool to conveniently and routinely assess tumor perfusion in conjunction with anti-cancer therapy. In a research setting, the proposed device will help determine if such a perfusion/therapy outcome relationship exists. In clinical oncology, this device will provide information to assess the success of tumor blood flow modification agents, to help plan anti-tumor therapy for mammal effectiveness and to unambiguously ensure that the biopsy is taken from viable, non-necrotic tissue. This low cost device will also allow the perfusion data to be collected without increased patient morbidity nor increased risk for seeding the normal surrounding tissue with tumor cells over that of a standard biopsy procedure. The ability of the sensor to detect significantly sized vessel within1-2mm may also help navigate the biopsy needle through tissue to avoid these vessels in the biopsy path. Future versions of this device may incorporate other physiologic sensors relevant to clinical interest. PROPOSED COMMERCIAL APPLICATION: The proposed instrumented biopsy needle for the measurement of tumor blood flow has the potential to predict the efficacy of non-surgical anti-tumor therapy for hundreds of thousands of patients in the US each year. This device should find wide application in many research centers studying tumor blood flow in animal models and humans. A low-cost biopsy needle adjunct which quantifies tissue viability and tissue ischemia, and permits sensing of vessels in close proximity to the needle tip to aid in navigation, is expected to have great commercial potential.